Please wait

 

As filed with the Securities and Exchange Commission on March 3, 2025

Registration No. 333-

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

 

FORM S-8

 

REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

 

Apogee Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware 93-4958665
(State or Other Jurisdiction of
Incorporation or Organization)
(I.R.S. Employer Identification No.)

 

 

221 Crescent St., Building 17, Suite 102b

Waltham, MA 02453

(650) 394-5230
(Address of Principal Executive Offices, Zip Code)

 

Apogee Therapeutics, Inc. 2023 Equity Incentive Plan

Apogee Therapeutics, Inc. 2023 Employee Stock Purchase Plan

(Full title of the plan)

 

Michael Henderson, M.D.

Chief Executive Officer

221 Crescent St., Building 17, Suite 102b

Waltham, MA 02453

(650) 394-5230
(Name and address of agent for service)

 

Copies to:

 

Matthew Batters

Chief Legal Officer and Secretary

221 Crescent St., Building 17, Suite 102b

Waltham, MA 02453

(650) 394-5230

Ryan A. Murr
Branden C. Berns
Melanie E. Neary
Gibson, Dunn & Crutcher LLP
One Embarcadero Center, Suite 2600
San Francisco, CA 94111
(415) 393-8373

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company" in Rule 12b-2 of the Exchange Act.

 

       
Large accelerated filer x Accelerated filer ¨
       
Non-accelerated filer ¨ Smaller reporting company ¨
       
    Emerging growth company ¨

 

 

 

 

 

EXPLANATORY NOTE

 

This Registration Statement on Form S-8 is filed by Apogee Therapeutics, Inc. (the “Registrant”) relating to (i) 2,903,144 shares of its common stock, par value $0.00001 per share (the “Common Stock”), available for issuance pursuant to future awards to eligible persons under the Apogee Therapeutics, Inc. 2023 Equity Incentive Plan and (ii) 580,628 shares of Common Stock issuable to eligible persons under the Apogee Therapeutics, Inc. 2023 Employee Stock Purchase Plan.

 

The information contained in the Registrant’s registration statements on Form S-8 filed with the Securities and Exchange Commission on May 13, 2024 (File No. 333-279354) and August 28, 2023 (File No. 333-274234), together with all exhibits filed therewith or incorporated therein by reference, is hereby incorporated by reference pursuant to General Instruction E to Form S-8 regarding the Registration of Additional Securities, except as amended hereby.

 

 

 

PART II

 

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

 

Item 8.                  Exhibits.

 

Exhibit No.       Exhibit Description
 
4.1 Amended and Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q filed on August 28, 2023).
 
4.2 Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.2 to the Company’s Quarterly Report on Form 10-Q filed on August 28, 2023).
 
5.1* Opinion of Gibson, Dunn & Crutcher LLP.
 
23.1* Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.
 
23.2* Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1).
 
24.1* Power of Attorney (included on signature page hereto).
 
99.1 Apogee Therapeutics, Inc. 2023 Equity Incentive Plan (incorporated by reference to Exhibit 10.9 of the Company’s Quarterly Report on Form 10-Q filed on August 28, 2023).
 
99.2 Apogee Therapeutics, Inc. 2023 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.15 to the Company’s Registration Statement on Form S-1/A filed on July 10, 2023).
 
107.1* Filing Fee Table.

 

 

*Filed herewith.

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Waltham, Commonwealth of Massachusetts, on this 3rd day of March, 2025.

 

  Apogee Therapeutics, Inc.
     
  By: /s/ Michael Henderson
  Name: Michael Henderson, M.D.
  Title: Director and Chief Executive Officer

 

POWER OF ATTORNEY

 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Michael Henderson, M.D. and Matthew Batters, and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and any registration statement relating to the offering covered by this Registration Statement and filed pursuant to Rule 462 under the Securities Act, and to file the same, with exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents or their substitute or substitutes may lawfully so or cause to be done by virtue hereof.

 

Pursuant to the requirements of the Securities Act, the following persons have signed this Registration Statement in the capacities and on the date(s) indicated.

 

Signature   Title   Date  
         
/s/ Michael Henderson   Director and Chief Executive Officer (Principal Executive Officer)   March 3, 2025
Michael Henderson, M.D.      
         
/s/ Jane Pritchett Henderson   Chief Financial Officer (Principal Financial and Accounting Officer)   March 3, 2025
Jane Pritchett Henderson      
         
/s/ Mark C. McKenna   Chair and Director   March 3, 2025
Mark C. McKenna        
         
/s/ Lisa L. Bollinger   Director   March 3, 2025
Lisa L. Bollinger, M.D.        
         
/s/ Jennifer Fox   Director   March 3, 2025
Jennifer Fox        
         
/s/ Andrew Gottesdiener   Director   March 3, 2025
Andrew Gottesdiener, M.D.        
         
/s/ Peter Harwin   Director   March 3, 2025
Peter Harwin        
         
/s/ William Jones, Jr.   Director   March 3, 2025
William Jones, Jr.        
         
/s/ Tomas Kiselak   Director   March 3, 2025
Tomas Kiselak        
         
/s/ Nimish Shah   Director   March 3, 2025
Nimish Shah